Oral News and Research

RSS

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.

1 Sep 2015

Scientists elucidate chemical process behind eosinophilic esophagitis

Scientists from the D'Or Institute of Research and Education, the Federal University of Rio de Janeiro and the Yale University School of Medicine have elucidated the chemical process behind a mysterious gastrointestinal disease that is becoming more frequent every day: the eosinophilic esophagitis (EoE), also known as the "asthma of the esophagus".

1 Sep 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Prolonged television watching associated with twice the risk of fatal pulmonary embolism

Prolonged television watchers have a higher risk of fatal pulmonary embolism, a condition associated with long haul flights, reveals research presented at ESC Congress today by Mr Toru Shirakawa, public health research fellow in the Department of Social Medicine at Osaka University in Japan.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.

31 Aug 2015

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

The combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full doses of either alone, researchers from the PATHWAY 3 study have found.

31 Aug 2015

ESC guideline adherent antithrombotic management improves outcomes in AF patients

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace.

31 Aug 2015

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

31 Aug 2015

Single dose of cocaine can impair ability to recognise negative emotions

A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.

31 Aug 2015

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

29 Aug 2015

New ESC Guidelines on infective endocarditis support role of imaging in diagnosis

ESC Guidelines published today on infective endocarditis boost the role of imaging in diagnosis of this deadly disease.

29 Aug 2015

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.

28 Aug 2015

Smiling Brazil initiative sets example to other nations to eliminate healthcare disparities

Today, the International and American Associations for Dental Research (IADR/AADR) published a Discovery! article titled "10 Years of a National Oral Health Policy in Brazil: Innovation, Boldness and Numerous Challenges."

28 Aug 2015

History of oral contraceptive use influences survival in ovarian cancer patients

A history of oral contraceptive use and having at least one child increased longevity by nearly three years in patients diagnosed with ovarian cancer, according to a Roswell Park Cancer Institute study recently published online ahead of print in the International Journal of Gynecological Cancer.

28 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

Oral News and Research

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Scientists elucidate chemical process behind eosinophilic esophagitis

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Prolonged television watching associated with twice the risk of fatal pulmonary embolism

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Educational program does not influence patients’ adherence to apixaban anticoagulant

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

ESC guideline adherent antithrombotic management improves outcomes in AF patients

MRA therapy does not improve outcome in heart attack patients without heart failure

Single dose of cocaine can impair ability to recognise negative emotions

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

New ESC Guidelines on infective endocarditis support role of imaging in diagnosis

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Smiling Brazil initiative sets example to other nations to eliminate healthcare disparities

History of oral contraceptive use influences survival in ovarian cancer patients

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News